EichorEICHOR
Condition: Hla A 02 01 Positive Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Hla A 02 01 Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Phase 2 · 2 location(s) · Sarcoma Alliance for Research through Collaboration · NCT06942442Adjuvant Tebentafusp in High Risk Ocular Melanoma
Phase 3 · 15 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06246149Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Phase 1/Phase 2 · 13 location(s) · Immunocore Ltd · NCT06840119Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 3 · 82 location(s) · Immunocore Ltd · NCT05549297A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H
Phase 1 · 18 location(s) · AstraZeneca · NCT05877599A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid M
Phase 1 · 2 location(s) · Zelluna Immunotherapy AS · NCT07613723MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Phase 1/Phase 2 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06424340IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Phase 3 · 211 location(s) · Immunocore Ltd · NCT06112314Study of IMC-P115C in Advanced PRAME-Positive Cancers
Phase 1 · 13 location(s) · Immunocore Ltd · NCT07156136
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.